Protein

Therapeutics

We have extensive experience drafting and prosecuting patent applications in the field of engineered peptide therapeutics, gaining insight into the different challenges that working in this area raises as compared to patenting antibody or polypeptide therapeutics. Our experience includes work on portfolios covering approved and candidate peptide therapeutics, such as Lixisenatide, Danegaptide, Glepaglutide and Dasiglucagon.

Many of these challenges revolve around the evolution of an initial wild-type peptide to become a candidate peptide therapeutic, modifying or truncating the wild-type peptide and often incorporating other types of derivatisation and cyclisation to optimise the properties of the therapeutic molecule. This work requires an understanding of underlying biochemistry and chemistry of the molecules.

In addition, the team at Mewburn Ellis working in this area have extensive experience of freedom-to-operate analysis, EPO opposition and appeals and other strategies to manage the competitive landscape, while maximising the protection of the products of the applicants we represent.

opps-report-1-1-1-1

Opposition Trends in the Life Sciences Sector

Special Report

In spring 2019, Mewburn Ellis undertook 350 hours of research, analysing more than 5,000 opposition cases filed at the European Patent Office over the last ten years, studying the timelines for hundreds of life sciences oppositions both before and after the EPO’s opposition streamlining initiative.

View the 2020 addendum for this report, based on information as it appeared on the EPO Register on 10 January 2021 and from bulk data sets extracted on this date.

Download the Report

Read our Blogs

UPC Weekly - Very appealing – preliminary injunction overturned

UPC Weekly - Very appealing – preliminary injunction overturned

by Matthew Naylor

2024 Week 49 SharkNinja have managed to persuade the UPC Court of Appeal to overturn a preliminary injunction awarded to Dyson. We investigate what made the difference in the appeal and consider what ...

UPC Weekly - Front-loading and obviousness at the UPC

UPC Weekly - Front-loading and obviousness at the UPC

by Matthew Naylor

2024 Week 48 In NJOY v VMR, the UPC Central Division Paris revoked VMR’s patent EP 3456214 B2 on 27 November 2024. The patent was held to be obvious, despite being maintained in amended form by the ...

UPC Weekly - UPC finds infringement using a doctrine of equivalents

UPC Weekly - UPC finds infringement using a doctrine of equivalents

by Matthew Naylor

2024 Week 47 Back in June 2024 (UPC Weekly 2024 week 23), we set out a few “known unknowns” – important developments in UPC case law that we expected to come in due course. New UPC decision Plant-e v ...

Resistance is futile – how new tech tackles AMR

Resistance is futile – how new tech tackles AMR

by Emily Lythell

Antimicrobial resistance (AMR) refers to the ability of microorganisms—bacteria, viruses, fungi, and parasites—to evolve and resist the effects of drugs that once effectively killed or inhibited ...

UPC Weekly - UPC dials up the advantages for patentees

UPC Weekly - UPC dials up the advantages for patentees

by Matthew Naylor

2024 Week 46 We report this week on two new UPC decisions that make the UPC an even more attractive choice for patent holders seeking to enforce their European patents. The headlines are that: (i) ...

Cambiotics: a novel treatment for PFAS ‘forever chemicals’

Cambiotics: a novel treatment for PFAS ‘forever chemicals’

by Eliot Ward

PFAS are toxic pollutants causing health problems globally. There is currently no treatment. Now a Danish startup is producing a probiotic, which it claims, flushes out the toxins via natural ...

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.